Evidence map›Paper›PMID 32617849›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2020

Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden.

Björn Eliasson, Jan Ekelund, Mervete Miftaraj, Mattis Flyvholm Ranthe, Ann-Charlotte Mårdby, João Diogo Da Rocha Fernandes, Ann-Marie Svensson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Adherence and Persistence to Basal Insulin Among People with Type 2 Diabetes in Europe: A Systematic Literature Review and Meta-analysis.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Björn EliassonDepartment of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden. bjorn.eliasson@gu.se.ORCID http://orcid.org/0000-0003-2569-4160
Jan EkelundCentre of Registers Västra Götaland, Gothenburg, Sweden.
Mervete MiftarajCentre of Registers Västra Götaland, Gothenburg, Sweden.
Mattis Flyvholm RantheNovo Nordisk A/S, Søborg, Denmark.
Ann-Charlotte MårdbyMedical Affairs, Novo Nordisk, Malmö, Sweden.
João Diogo Da Rocha FernandesNovo Nordisk A/S, Søborg, Denmark.
Ann-Marie SvenssonDepartment of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
Centre of Registers Vastra Gotaland · SENovo Nordisk (Denmark) · DKSahlgrenska University Hospital · SEUniversity of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo explore persistence with insulin degludec/liraglutide (IDegLira) treatment, clinical characteristics and concomitant medications in a large population of patients in clinical practice.

methodsThis was an observational study in patients with type 2 diabetes (n = 2432) who initiated IDegLira between 26 May 2015 and 31 December 2017. Data were obtained from Swedish nationwide registers and linked on an individual level using unique Swedish personal identifiers. Dose calculations were made for patients with ≥ 180 days between the first and last collections of IDegLira prescription. Changes in clinical parameters were evaluated as change from the last observation during 12 months prior to the initiation date until ± 90 days from the last collection of IDegLira.

resultsPre-index regimens (index date being the date of filling the first prescription of IDegLira) included: multiple daily insulin injections (45.1%); insulin and glucagon-like peptide-1 receptor agonist (GLP-1 RA) (19.7%); long-acting insulins (11.8%); non-injectable therapy only (11.4%); GLP-1 RA only (9.8%); and no collection of diabetes medication during the 6-month pre-index period (2.3%). The majority of patients (94 and 84%) were persistent with IDegLira at 6 and 12 months, respectively. The most commonly used concomitant medication was metformin (69.4%). Mean daily dose was 33 dose steps. Overall, there was a mean decrease in HbA1c (approx. 10 mmol/mol [1%]) and body weight (- 1.1 kg). Improvements in HbA1c were observed regardless of pre-index treatment.

conclusionAfter 12 months, 84% of patients were persistent on IDegLira, with improved glycaemic control and reductions in body weight.

Indexed as

GLP-1 analogueInsulin therapyLiraglutideReal-worldType 2 diabetes

Identifiers

PMID32617849
PMCPMC7376998
OpenAlexW3039447298

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.